Viyash Scientific stock analysis
Want to see IN:VIYASH full AI Analyst Report?
Viyash Scientific (VIYASH) Stock Price & Analysis
VIYASH Stock Chart & Stats
- Day’s Range
- INR 240.10 - INR 257.10
- 52-Week Range
- INR 178.40 - INR 297.90
- Previous Close
- INR 237.75
- Volume
- N/A
- Average Volume (3M)
- 168.91K
- Market Cap
- INR 104.93B
- Enterprise Value
- INR 85.83B
- Total Cash (Recent Filing)
- INR 2.59B
- Total Debt (Recent Filing)
- INR 0
- Price to Earnings (P/E)
- 60.8
- Beta
- 1.07
- Next Earnings
- Nov 13, 2026 (Est.)
- EPS Estimate
- 1.7
- Last Dividend Ex-Date
- Sep 08, 2021
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Margin Expansion
The combination of dramatic 2026 revenue growth and higher EBIT and EBITDA margins indicates improving operating scale and profitability. If maintained, this stronger earnings base can support reinvestment, improve resilience, and establish a more competitive position over the next several quarters.
Lower Financial Leverage
A materially lower debt-to-equity ratio gives Viyash Scientific a stronger capital position and greater financial flexibility. Reduced leverage can limit balance-sheet strain, improve capacity to fund operations, and provide more room to withstand earnings variability while pursuing future growth.
Improving Free Cash Flow
The return to solidly positive free cash flow is an important improvement in the company’s ability to fund itself internally. Stronger cash generation can support investment and balance-sheet flexibility, provided the improvement persists beyond the recent earnings rebound.
Bears Say
Earnings Volatility
Recent profitability has not yet demonstrated consistent stability because the company experienced losses in 2023–2024 and negative EBIT margins during that period. Continued volatility could make earnings harder to forecast and weaken confidence that current margins represent a durable operating level.
Weak Cash Conversion
Although cash generation improved, the relatively small operating-cash-flow contribution and free cash flow below half of net income indicate incomplete earnings conversion. This can constrain internally funded growth and leave results sensitive to capital spending or working-capital movements.
Unproven Capital Efficiency
The return to positive return on equity is encouraging, but the preceding negative levels show that capital efficiency has not been consistently established. Sustained improvement will be important to demonstrate that the stronger balance sheet is producing dependable returns rather than only reflecting financial recovery.
Viyash Scientific News
VIYASH FAQ
What was Viyash Scientific’s price range in the past 12 months?
What is Viyash Scientific’s market cap?
When is Viyash Scientific’s upcoming earnings report date?
How were Viyash Scientific’s earnings last quarter?
Is Viyash Scientific overvalued?
Does Viyash Scientific pay dividends?
What is Viyash Scientific’s EPS estimate?
How many shares outstanding does Viyash Scientific have?
What happened to Viyash Scientific’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Viyash Scientific?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Viyash Scientific
Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, including nutritional support, pain relief, parasite control, antibiotic treatments, and gut health solutions. These products cater to various animals like livestock, poultry, and domestic pets. Additionally, the company extends its expertise through analytical testing and specialized veterinary formulation services. Originally established as Sequent Scientific Limited, the company officially adopted the name Viyash Scientific Limited in January 2026. Founded in 1985, its corporate headquarters are situated in Hyderabad, India. Currently, Viyash Scientific Limited functions as a subsidiary of CA Harbor Investments.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Haribabu Bodepudi
- Employees
- 1,244
- Website
- www.viyash.com
- Address
- Srivallis Corporate, Hyderabad, MA, 500033, IN
Viyash Scientific (VIYASH) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 2 | 8 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 9 | 0 | 3 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:AKUMSAkums Drugs and Pharmaceuticals Limited | ||
| IN:APLLTDAlembic Pharmaceuticals Limited | ||
| IN:CAPLIPOINTCaplin Point Laboratories Limited | ||
| IN:ALIVUSGlenmark Life Sciences Limited | ||
| IN:STARStrides Pharma Science Ltd |









